SkinBioTherapeutics has provided a development update for its two lead commercial programmes, demonstrating strong progress towards accessing two significant market opportunities, cosmetic ingredients and psoriasis. Sederma, the division of Croda which is developing SkinBiotix, has completed initial manufacturing development and has progressed to scale up validation. Following completion of the AxisBiotix formulation development ahead of schedule, SBTX has established a protocol for a self-manag ....
31 Jul 2020
Cenkos: SkinBioTherapeutics Plc - Significant progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: SkinBioTherapeutics Plc - Significant progress
SkinBioTherapeutics Plc (SBTX:LON) | 9.2 0 (-5.1%) | Mkt Cap: 18.5m
- Published:
31 Jul 2020 -
Author:
Chris Donnellan -
Pages:
6
SkinBioTherapeutics has provided a development update for its two lead commercial programmes, demonstrating strong progress towards accessing two significant market opportunities, cosmetic ingredients and psoriasis. Sederma, the division of Croda which is developing SkinBiotix, has completed initial manufacturing development and has progressed to scale up validation. Following completion of the AxisBiotix formulation development ahead of schedule, SBTX has established a protocol for a self-manag ....